| TOTAL: $12M | |||
| Year to Date: $127.21M | |||
| Company (Symbol)#* | Partner (Country) | Amt (M) | Details (Date) |
| Albany Molecular Research Inc. (AMRI) | Bristol-Myers Squibb Co. | $4 | For the submission of a clinical trial application to the Medical Products Agency in Sweden to start Phase I studies of an undisclosed AMRI compound (5/26) |
| ChemoCentryx Inc.* | GlaxoSmithKline plc (UK) | $5 | For identifying a small-molecule antagonist of the C5a receptor (5/5) |
| Emisphere Technologies Inc. (EMIS) | MannKind Corp. (MNKD) | $0.5 | For MannKind's filing and the FDA's acceptance of the new drug application for Afresa, an ultra rapid-acting insulin (5/21) |
| MorphoSys AG (Germany; FSE:MOR) | Novartis AG (Switzerland) | ND | For Novartis filing documentation to start a Phase I trial with a HuCAL-derived fully human antibody (5/5) |
| Regulus Therapeutics Inc.* | GlaxoSmithKline plc (UK) | ND | For the successful delivery of specific microRNA inhibitors, known as anti-miRs, to mice and for the identification of changes in expression of the genes regulated by the micro-RNA in immune cells (5/14) |
| Vical Inc. (VICL) | AnGes MG Inc. (Japan) | $2.5 | Related to continued progress in the company's ongoing Phase III trial of its Allovectin-7 immunotherapeutic in metastatic melanoma (5/18) |
| Notes: | |||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. | |||
| * Private company. Currency conversions are based on exchange rates at the time of the deal. | |||
| ND = Not disclosed. FSE = Frankfurt Stock Exchange. | |||
